Ascending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women. [electronic resource]
Producer: 20140422Description: 1782-8 p. digitalISSN:- 1930-739X
- 3-Hydroxybutyric Acid -- blood
- Adiponectin -- blood
- Aminopeptidases -- antagonists & inhibitors
- Anti-Obesity Agents -- adverse effects
- Aspergillus -- chemistry
- Biological Products -- adverse effects
- Blood Glucose -- metabolism
- Blood Pressure
- C-Reactive Protein -- metabolism
- Cholesterol, LDL -- blood
- Cyclohexanes -- adverse effects
- Double-Blind Method
- Fatty Acids, Unsaturated -- adverse effects
- Female
- Fibroblast Growth Factors -- blood
- Glycoproteins -- antagonists & inhibitors
- Humans
- Hunger -- drug effects
- Infusions, Intravenous
- Leptin -- blood
- Lipids -- blood
- Methionyl Aminopeptidases
- Middle Aged
- Obesity -- blood
- Sesquiterpenes -- adverse effects
- Triglycerides -- blood
- Weight Loss -- drug effects
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.